CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Mizagliflozindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05541939
NCT05541939Phase 2Completed
CompareCT.gov

Phase 2 Randomized Single Ascending Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin Formulations on Postprandial Glucose and Insulin Levels

Vogenx, Inc.·interventional·Posted Sep 15, 2022·Updated Jun 25, 2024

In Brief

A Phase 2 clinical trial evaluating Mizagliflozin for Postbariatric Hypoglycemia. Completed, enrolled 9 participants across 2 sites.

Detailed Summary

This clinical study will examine the safety and tolerability, as well as the effects of orally administered mizagliflozin on post prandial glucose and insulin levels in subjects diagnosed with post-bariatric hypoglycemia (PBH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostbariatric Hypoglycemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedSep 15, 2022
Enrollment StartSep 13, 2022
Primary CompletionFeb 17, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.8 years ago

Interventions

Mizagliflozindrug

Encapsulated or Liquid Formulation